Non-Hodgkin’s Lymphoma

Show Only Open Trials
1.

An Open-label, Multicenter, Single-arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects with Refractory Follicular Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: Janssen
  • Disease Status and/or Stage: Refractory Follicular Lymphoma
  • Protocol ID: PCI-32765FLR2002
2.

A Phase II Trial to Evaluate the Efficacy of Fostamatinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: AstraZeneca
  • Disease Status and/or Stage: Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
3.

A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients with Previously Undiagnosed Peripheral T-cell Lymphoma Who Have Achieved an Objective Response Following Initial Treatment with CHOP-based Chemotherapy

  • Study Status: Open to Enrollment
  • Sponsor: Allos Therapeutics
  • Disease Status and/or Stage: Peripheral T-Cell Lymphoma
  • Protocol ID: PDX-017
4.

A Pilot Study of a Sequential Regimen of Intensive Chemotherapy Followed by Autologous or Allogeneic Transplantation for Refractory Lymphoma (Non-Hodgkin's and Hodgkin's)

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Refractory Lymphoma (non-Hodgkin and Hodgkin) in Need of Stem Cell Transplant
5.

A Multicenter Phase 1-2 Study of MLN8237, an Oral Aurora A Kinase Inhibitor, in Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma Treated with Rituximab and Vincristine

  • Study Status: Open to Enrollment
  • Sponsor: Millennium
  • Disease Status and/or Stage: Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma, Mantle Cell Lymphoma or Burkitt Lymphoma
  • Protocol ID: C14011
6.

Combination Veltuzumab (Anti-CD20) and Fractionated 90Y- Epratuzumab (Anti-CD22) Radioimmunotherapy in Patients with Follicular Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Follicular Lymphoma
7.

Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: Eastern Cooperative Oncology Group
  • Disease Status and/or Stage: Untreated Mantle Cell Lymphoma, Age 60 & Older
  • Protocol ID: E1411
8.

A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator's Choice (Selected Single Agent) in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: Millennium
  • Disease Status and/or Stage: Relapsed/Refractory Peripheral T-Cell Lymphoma
  • Protocol ID: C14012
9.

A Phase 2, Multicenter, Single-Arm Study to Evaluate the Efficacy and Safety of Single-Agent Bruton's Tyrosine Kinase (Btk) Inhibitor, Ibrutinib, in Subjects with Mantle Cell Lymphoma Who Progress after Bortezomib Therapy

  • Study Status: Open to Enrollment
  • Sponsor: Janssen
10.

A Randomized study of Combined Haplo-identical Umbilical Cord Transplantation vs. Double Umbilical Cord Transplantation in Patients with Hematologic Malignancies

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Hematologic Malignancies in Need of Donor Stem Cell Transplant
11.

BMT CTN 0903 - Allogeneic Hematopoietic Cell Transplant for Hematological Cancers and Myelodysplastic Syndromes in HIV-Infected Individuals

  • Study Status: Open to Enrollment
  • Sponsor: BMT-CTN
  • Disease Status and/or Stage: Hematologic Cancers and Myelosysplastic Syndromes in HIV-Positive People
  • Protocol ID: BMT CTN 0903
12.

CALGB 50901: A Phase II Trial of Ofatumumab (CALGB IND #112390) in Previously Untreated Follicular Non-Hodgkin's Lymphoma (NHL)

  • Study Status: Open to Enrollment
  • Sponsor: CALGB
  • Disease Status and/or Stage: Untreated Follicular Lymphoma
  • Protocol ID: CALGB 50901
13.

S1108: A Phase II Trial of the Aurora Kinase A Inhibitor MLN8237, in Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: SWOG
  • Disease Status and/or Stage: Relapsed/Refractory Peripheral T-Cell non-Hodgkin Lymphoma
14.

Phase I/II Study of Veltuzumab Combined with 90Y-Epratuzumab Tetraxetan in Patients with Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: Immunomedics
15.

Phase 2 Study to Assess the Efficacy and Safety of CAL-101 in Patients with Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents

  • Study Status: Open to Enrollment
  • Sponsor: Calistoga
  • Disease Status and/or Stage: Refractory Indolent B-cell non-Hodgkin Lymphoma
16.

CALGB 50904: A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC #681239, IND #58443) and Bendamustine in Patients with Untreated Follicular Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: CALGB
  • Disease Status and/or Stage: Untreated Follicular Lymphoma
  • Protocol ID: CALGB 50904
17.

A Multicenter, Open-label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects with Relapsed or Refractory De Novo diffuse Large B-Cell Lymphoma (PCYC 1106)

  • Study Status: Open to Enrollment
  • Sponsor: Pharmacyclics
  • Disease Status and/or Stage: Relapsed or Refractory de Novo Diffuse Large B-cell Lymphoma (DLBCL)
18.

An Open-Label, Dose Escalation, Phase 1 Study of MLN9708, A Second-Generation Proteasome Inhibitor, in Adult Patients with Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: Millennium
  • Disease Status and/or Stage: Relapsed or Refractory Lymphoma (non-Hodgkin and Hodgkin)
19.

Coping with Lymphoma to Enhance Adjustment and Reduce Stress in Survivors (CLEAR Stress)

  • Study Status: Open to Enrollment
  • Sponsor: Agency for Healthcare Research and Quality; Weill Cornell Medical College
20.

Phase II Study of Lenalidomide plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Untreated Mantle Cell Lymphoma
21.

Phase I/II Trial of Azacytidine + R-CHOP in Diffuse Large B-Cell Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Diffuse Large B-Cell Lymphoma (DLBCL)
22.

Phase I/II study of combination epigenetic therapy with azacitidine and vorinostat in patients with relapsed and refractory DLBCL

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Relapsed or Refractory Diffuse Large B-Cell Lymphoma
23.

A long-term Safety Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia

  • Study Status: Open to Enrollment
  • Sponsor: Pharmacyclics, Inc.
24.

An Open-Label, Randomized, Phase 2 Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients

  • Study Status: Open to Enrollment
  • Sponsor: Millennium Pharmaceuticals
  • Disease Status and/or Stage: Previously untreated Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma
25.

Phase 1 Study of PD 0332991 Plus Bortezomib in Patients with Previously Treated Mantle Cell Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Mantle Cell Lymphoma (MCL)
26.

Multicenter Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Relapsed or Refractory Mantle Cell Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: Pharmacyclics
  • Disease Status and/or Stage: Mantle Cell Lymphoma (MCL)
27.

Phase 1 Study of Radiosensitization using Bortezomib in Patients with Relapsed Non-Hodgkin's Lymphoma receiving Radioimmunotherapy

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Relapsed or Refractory Non-Hodgkin's Lymphoma
28.

A Phase II, Single Institution, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of a Single Agent Dasatinib (Sprycel®) in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)
29.

CALGB 50303: Phase III Randomized Study of R-CHOP vs. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-cell Lymphomas

  • Study Status: Open to Enrollment
  • Sponsor: Cancer and Leukemia Group B; National Cancer Institute
  • Disease Status and/or Stage: Untreated De Novo Diffuse Large B-Cell Lymphoma with Stage II, III or IV Disease
30.

Early Response Assessment in Patients with Diffuse Large B-Cell Lymphoma Using 18-fluoro-2-deoxyglucose positron emission tomography (FDG-PET)

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Untreated CD20+ Diffuse Large B-Cell Lymphoma (DLBCL) of Any Stage
31.

Phase I trial of anti-CD74 (hLL1) Antibody Therapy in B-cell malignancies

  • Study Status: Closed to Enrollment
  • Sponsor: Weill Cornell Medical College; Immunomedics, Inc.
Top of page